Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VNDA vs OMER: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OMER Captures Overall Composite Edge (54.1 HOLD vs 49.0 HOLD), While VNDA Leads 3–2 on Growth & Valuation Pillars

OMER Overall Winner 6-Pillar Tally: VNDA 3 – 2 OMER (1 Tie) Matrix Metrics: VNDA 3 – 7 OMER

As of Nov 16, 2026, Omeros Corporation (OMER) captures the overall head-to-head institutional edge over Vanda Pharmaceuticals Inc. (VNDA) on higher Unified Composite conviction (54.1/100 HOLD vs. 49.0/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Options & Positioning), while VNDA wins 3–2 across the 6-pillar growth and valuation breakdown. VNDA trades at $3.79 (103.1x Forward P/E, -77.6% operating margin) versus OMER at $17.18 (75.8x Forward P/E, -189.5% operating margin).

  • Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (54.1/100 HOLD vs. VNDA 49.0/100 HOLD) and 1.81β · 54% Vol risk profile, whereas VNDA leads top-line expansion (+24.1% YoY revenue growth, 2.23x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile OMER trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VNDA vs OMER
VNDA NASDAQ
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46
OMER NASDAQ Head-to-Head Winner
Omeros Corporation
Pharmaceutical Preparations
$17.18
-1.8% 1D
Market Cap $1.3B
TTM Revenue $27M
Forward P/E 75.8x
Beta / 30D Vol 1.81β · 54% Vol
Unified Composite Score
54.1 / 100 HOLD
Tech 44.0 Fund 55.0 Flow 74.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $17.47 · SMA50: $18.23

6-Pillar Scorecard Institutional Category Breakdown (VNDA 3 – 2 OMER)

Columns: Metric · VNDA · OMER
1. Valuation Multiples OMER
Forward P/E 103.1x 75.8x
Trailing P/E 103.1x 14.9x
PEG Ratio 2.23x 0.81x
EV / Revenue 0.9x 51.9x
2. Growth & Scale VNDA
Revenue Growth (YoY) +24.1% +14.9%
Earnings Growth (YoY) -95.9% +0.0%
TTM Revenue (USD) $229M $27M
Market Cap $238.9M $1.3B
3. Profitability & Quality VNDA
Gross Margin 93.6% 38.3%
Operating Margin -77.6% -189.5%
Net Profit Margin -119.9% 324.9%
Return on Equity (ROE) -82.5% -576.3%
4. Balance Sheet & Cash Flow VNDA
Cash Generation (TTM) -$150M -$48M
Cash Flow Margin -65.4% N/A
Net Cash / Leverage $40M Net Cash $96M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OMER
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 163.3% (75th %ile) 147.9% (99th %ile)
Put/Call OI Skew N/A 0.09x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VNDA (3) vs OMER (7)
Institutional Metric VNDA OMER Criterion Row Edge
Market Capitalization
Scale
$238.9M $1.3B Larger Scale OMER
Trailing P/E Ratio
Valuation
103.1x 14.9x Lower Multiple OMER
Forward P/E Ratio
Valuation
103.1x 75.8x Lower Multiple OMER
Revenue Growth (YoY)
Growth
+24.1% +14.9% Higher Growth VNDA
Operating Margin (TTM)
Profitability
-77.6% -189.5% Higher Margin VNDA
Net Profit Margin
Profitability
-119.9% 324.9% Higher Margin OMER
Return on Equity (ROE)
Capital Efficiency
-82.5% -576.3% Higher ROE VNDA
52-Week Range Position
Momentum
4% ($4–$10) 73% ($6–$21) Stronger Trend OMER
Beta / 30D Volatility
Risk Regime
1.25β · 61% Vol 1.81β · 54% Vol Lower Realized Risk OMER
Unified Institutional Score
Composite Signal
49.0 / 100 (HOLD) 54.1 / 100 (HOLD) Higher Composite OMER
Trailing 12M Revenue (USD)
Operating Scale
$229M $27M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
93.6% 38.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.23x PEG · 0.9x EV/Rev 0.81x PEG · 51.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($40M Net Cash) -$48M ($96M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OMER +11.85 pp
VNDA: -5.83% · OMER: +6.02%
3M Horizon OMER +30.15 pp
VNDA: -30.24% · OMER: -0.09%
6M Horizon OMER +84.37 pp
VNDA: -37.58% · OMER: +46.79%
1Y Horizon OMER +186.05 pp
VNDA: -12.56% · OMER: +173.49%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VNDA Revenue OMER Revenue VNDA Op. Margin OMER Op. Margin Margin Leader
FY2018 $190M $30M 11.3% -375.7% VNDA
FY2019 $230M $110M 10.0% -130.6% VNDA
FY2020 $250M $70M 11.0% -212.6% VNDA
FY2021 $270M N/A 15.7% N/A VNDA
FY2022 $250M N/A 2.5% N/A VNDA
FY2023 $190M N/A -7.2% N/A VNDA
FY2024 $200M N/A -20.5% N/A VNDA
FY2025 $220M N/A -70.0% N/A VNDA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OMER CONSOLIDATION
39d in phase · OBV DISTRIBUTION
Current IV 147.9%
IV Percentile 99th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact OMER Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OMER Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -189.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VNDA vs OMER Key Questions & Quantitative Answers

As of Nov 16, 2026, Omeros Corporation (OMER) captures the overall head-to-head institutional edge over Vanda Pharmaceuticals Inc. (VNDA) on higher Unified Composite conviction (54.1/100 HOLD vs. 49.0/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Options & Positioning), while VNDA wins 3–2 across the 6-pillar growth and valuation breakdown. VNDA trades at $3.79 (103.1x Forward P/E, -77.6% operating margin) versus OMER at $17.18 (75.8x Forward P/E, -189.5% operating margin). Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (54.1/100 HOLD vs. VNDA 49.0/100 HOLD) and 1.81β · 54% Vol risk profile, whereas VNDA leads top-line expansion (+24.1% YoY revenue growth, 2.23x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile OMER trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VNDA leads the Growth & Scale pillar: VNDA posts +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin), compared with OMER at +14.9% YoY revenue growth and +0.0% YoY earnings growth on $27M TTM revenue (38.3% gross margin, -189.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VNDA cumulative revenue shifted +15.8% while OMER shifted +133.3%. In operating R&D and SG&A reinvestment, VNDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OMER.

OMER screens cheaper on headline valuation multiples. VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin), whereas OMER trades at 75.8x Forward P/E, 14.9x Trailing P/E, 0.81x PEG, and 51.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VNDA (-82.5% ROE) versus OMER (-576.3% ROE) capital efficiency.

In options market volatility and institutional positioning, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk). By comparison, OMER carries 147.9% implied volatility (99th %ile, Extreme (>80th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.81β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.